25,729 articles
Zuclopenthixol
Zuclopenthixol (Clopixol), cis-isomer of clopenthixol, a thioxanthene typical antipsychotic introduced in 1962; sold as oral dihydrochloride, short-acting acetate injection, and decanoate depot for schizophrenia.
ZUMA-1 trial
ZUMA-1 (NCT02348216) is the pivotal single-arm phase 1-2 trial of axicabtagene ciloleucel (KTE-C19, Yescarta) CAR T-cell therapy in refractory large B-cell lymphoma, reporting 83% ORR, 58% CR, and 42.6% five-year overall survival.
ZUMA-3 trial
ZUMA-3 (NCT02614066), also called the brexucabtagene autoleucel or KTE-X19 trial, is a single-arm phase 1/2 study of anti-CD19 CAR T therapy in adult relapsed/refractory B-ALL, with 70.9% CR/CRi and FDA approval in October 2021.
Zung Self-Rating Depression Scale
The Zung Self-Rating Depression Scale (SDS) is a 20-item self-report questionnaire that screens for and grades depression severity, producing a raw score from 20 to 80 and an index from 25 to 100.
Zuogui Yin
左归饮 (Zuogui Yin, Left-Restoring Decoction), a kidney-yin-nourishing TCM formula from Zhang Jiebin's Jingyue Quanshu; six herbs led by prepared rehmannia; treats genuine yin deficiency; distinct from the stronger 左归丸.
Zurletrectinib tablets
Zurletrectinib (佐来曲替尼, ICP-723, brand Yinuoxin) is InnoCare Pharma's second-generation pan-TRK and ROS1 inhibitor tablets, conditionally approved in China December 2025 for NTRK fusion-positive solid tumors, with 89.1% ORR and activity against G595R/G667C resistance.
ZVS101e (CYP4V2 AAV gene therapy)
ZVS101e, also registered as rAAV2/8-hCYP4V2, is an AAV gene therapy delivering a functional CYP4V2 gene by subretinal injection, developed by Chigenovo of Beijing to treat Bietti crystalline corneoretinal dystrophy.
ZX2021
ZX2021 (GGGF-1) is a Chinese Fc-fusion triple agonist of GCGR, GIPR, and GLP-1R by Jiangsu Zhongxin Pharmaceutical, in Phase 2 for obesity and type 2 diabetes.
ZyCoV-D
ZyCoV-D (Zydus Cadila) is the world's first authorized plasmid DNA COVID-19 vaccine, needle-free intradermal, 66.6% phase 3 efficacy, EUA in India August 2021, two-dose from April 2022.
Zygomatic bone
Zygomatic bone (os zygomaticum, zygoma, malar, cheekbone): paired facial bone forming the cheek prominence, lateral orbit wall, and zygomatic arch with the temporal bone; articulates with frontal, maxilla, temporal, sphenoid; homologous to the jugal.
Zygote Intrafallopian Transfer
Zygote intrafallopian transfer, also known as pronuclear stage tubal transfer or ZIFT, is a rarely performed assisted reproductive procedure that places IVF-created zygotes into the Fallopian tube.
ZYH7
ZYH7 (ZYH-7) is an investigational PPARα agonist for dyslipidemia developed by Zydus Cadila; IND filed 2007, phase 2 trial NCT01539616 versus fenofibrate completed.
ZYI1
ZYI1 (ZYI-1) was a Zydus Cadila small-molecule drug candidate for inflammation and pain, in Phase II trials by 2009; its mode of action was never disclosed and the program was abandoned in Phase 2.
ZYO1
ZYO1 (ZYO-1, ZY-01) was Zydus Cadila's small-molecule cannabinoid CB1 receptor antagonist for obesity, developed at the Zydus Research Centre, Ahmedabad; it completed Phase 2 trials in India and was then discontinued, one of 13 clinical candidates from Zydus's NCE program begun in 2000.
ZyVac TCV
ZyVac TCV (Typhoid Vi Conjugate Vaccine I.P.) is a Vi polysaccharide–tetanus toxoid conjugate typhoid vaccine by Zydus Lifesciences, India; licensed 2017, WHO-prequalified 21 October 2024, single 0.5 mL intramuscular dose for ages 6 months to 65 years.
Zyzz (Азиз Сергеевич Шавершян)
Zyzz (Aziz Sergeyevich Shavershian, Азиз Сергеевич Шавершян), Moscow-born Australian bodybuilder and early fitness influencer of the aesthetics movement; died in Thailand in 2011 at 22; subject of Poster Boy: Becoming Zyzz.
α-synuclein seed amplification assay
The α-synuclein seed amplification assay (αSyn-SAA) is an ultrasensitive laboratory test that amplifies misfolded α-synuclein seeds in cerebrospinal fluid to detect Parkinson's disease and related synucleinopathies.
Γ-Hydroxybutyric acid
Gamma-hydroxybutyric acid (GHB, sodium oxybate, Xyrem), an endogenous GABA analog. Schedule I drug of abuse and approved narcolepsy treatment; 20-60 min half-life, no overdose antidote, withdrawal up to 21 days.
Μ-opioid receptor
Μ-opioid receptor (MOR, OPRM1): principal 7-TM GPCR for endogenous opioid peptides and analgesic drugs; Gi/o signaling, β-arrestin desensitization; target of morphine, fentanyl, methadone, buprenorphine, naloxone.